Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Dark Horse Consulting Expands into China
Business business expansion

Dark Horse Consulting Expands into China

Analysis based on 7 articles · First reported Aug 11, 2026 · Last updated Aug 11, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The expansion positions DHCG to capture growth in China's life sciences consulting market, potentially increasing its revenue and client base. It signals confidence in China's biotech ecosystem, which may positively affect sentiment for related CDMO and CRO companies.

Life Sciences Consulting Biotechnology Contract Research Organizations
Event Summary

Dark Horse Consulting Group (DHCG), a life sciences consulting firm specializing in advanced therapies, announced the formation of Dark Horse Consulting China and the appointment of Kang Liu as its inaugural hire. The new Shanghai office aims to help biotherapeutic developers leverage China's CDMO/CRO infrastructure, regulatory pathways, and IIT route to generate first-in-human data. Kang Liu brings over 13 years of experience from ADMA Biologics and GenScript Biotech Corporation's CDMO division (now ProBio CDMO). DHCG is expanding in APAC, having acquired Tokyo-based CJP. The expansion reflects China's growing role in global biotech.

Key Actions
90 Dark Horse Consulting Group formed
80 Dark Horse Consulting Group appointed Kang Liu
70 Dark Horse Consulting Group acquired CJP
Entities Involved
priv
Dark Horse Consulting Group
Core entity; expands into China, appoints Kang Liu, and acquires CJP, strengthening its APAC presence and growth prospects.
Importance 100.0 Sentiment 60.0
per
Kang Liu
Appointed as head of China practice; brings extensive industry experience, enhancing DHCG's capabilities and credibility.
Importance 90.0 Sentiment 70.0
cnt
China
Beneficiary of DHCG's expansion; highlights China's growing life sciences ecosystem and attractiveness for biotech investment.
Importance 80.0 Sentiment 50.0
per
Anthony Davies
Founder and CEO; provides strategic vision and public endorsement of the expansion.
Importance 40.0 Sentiment 30.0
stock
ADMA Biologics
Kang Liu's former employer; indirectly referenced, no direct impact from this event.
Importance 30.0 Sentiment 20.0
oth
CJP
Acquired by DHCG as part of APAC expansion; integration may enhance DHCG's regional capabilities.
Importance 25.0 Sentiment 20.0
stock
GenScript Biotech Corporation
Kang Liu's former employer; indirectly referenced, no direct impact.
Importance 20.0 Sentiment 10.0
priv
ProBio CDMO
Former division of GenScript; indirectly referenced, no direct impact.
Importance 20.0 Sentiment 10.0
priv
Porton Advanced
MOU partner mentioned; may benefit from increased referrals through DHCG China.
Importance 15.0 Sentiment 10.0
priv
KunTuo
MOU partner mentioned; may benefit from increased referrals through DHCG China.
Importance 15.0 Sentiment 10.0
ngo
International Society for Cell & Gene Therapy
Kang Liu's professional affiliation; no direct impact from this event.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.